BioFocus and Almac collaborate to offer fluorescent lifetime assays

29-Mar-2011 - United Kingdom

BioFocus and Almac have initiated a collaboration which will provide BioFocus customers with compound screening and profiling services using Almac’s FLEXYTETM fluorescence lifetime (FLT) assays. FLT as a reading modality offers a robust, antibody free, homogeneous assay platform which enables the user to avoid interference from fluorescent compounds within a screening library.

BioFocus has launched an FLT screening and profiling service utilising the FLEXYTETM assay platform and now offer campaigns against targets including proteases, phosphatases and kinases. The unique properties of FLT have also been harnessed to open up access to previously inaccessible epigenetics target classes. Several approaches can be taken using the FLEXYTETM   platform including fragment based screens and kinetic profiling.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance